Fundamental XR expands access to immersive training with web-enabled platform

Tern plc

Fundamental XR has launched Immersive Web, a platform designed to extend immersive training beyond headset-only environments and into the browser.

The company’s core proposition has centred on delivering high-fidelity, hands-on training through virtual environments. While immersive hardware enables realistic and repeatable skill development, full deployment can require logistical planning, capital investment and on-site coordination. Immersive Web introduces a browser-based layer that allows elements of training to be accessed without dedicated equipment, widening the potential user base and reducing friction at the point of entry.

This approach alters the economics of implementation. Organisations can begin engagement through standard web browsers, enabling learners to complete preparatory modules, theoretical instruction and guided walkthroughs before progressing to fully immersive simulations. By separating foundational learning from advanced practical application, the platform supports a more staged investment model.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search